anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an intermediate-sized expanded access treatment protocol. GaM (GaM) will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days). Initially, the patients will be provided a three (3) cycle prescription (a 28-day supply with two refills); enough total supply of GaM for three full cycles to allow for self-administration at home. It should be taken on an empty stomach. After that initial period, subsequent GaM will be provided to patients for continued self-administration.

At the treating physician's discretion, additional medication(s) may be administered. Clinical use of cancer-supportive care therapies is unrestricted, but the non-emergent use of additional anti-cancer therapies requires prior consultation with xCures and Imaging Biometrics. xCures along with Imaging Biometrics will be consulted prior to the non-emergent administration of any additional anti-cancer medications. xCures, along with Imaging Biometrics, should be consulted prior to any schedule modifications or the addition of other therapy. The patients may discontinue therapy at any time for any reason. The treating physician can discontinue therapy with GaM at any time for any reason.
The invention belongs to the field of biological medicinal preparation and relates to a preparation technology and an application of a natural recombinant nanostructured lipid carrier. The specifically-refereed nanoparticle is natural recombinant lipoprotein drug-loaded nanoparticle and is prepared by in vitro recombination of an apolipoprotein mixture and lipid which are obtained by extraction and purification of a blood plasma ingredient IV and a medicament. The recombination process is realized by a film dispersion method, an emulsification-evaporation method or an emulsification-evaporation improved method. The technical problem to be solved in the invention is the extraction and purification method of apolipoprotein and lipid mixture and the preparation technology of the natural recombinant lipoprotein drug-loaded nanoparticle. Preparation conditions are mild, and costs are low. The natural recombinant lipoprotein nanoparticle provided by the invention has remarkable advantages of spheroidic structure, high bionic performance, high penetrability, efficient carrying performance, tumor targeting and the like. The invention provides property evaluation and application of the above natural recombinant lipoprotein nanoparticle. Normal saline, or a phosphate buffer or 5% glucose solution is added to dissolve the nanoparticle, and the dissolved nanoparticle can be used to treat diseases in a mode of intravenous injection, intramuscular injection, oral medication or cutaneous penetration. The technology provided by the invention is simple and low-cost and is easy for industrial production.
BACKGROUND: Sudden death is defined as an unexpected death occurring with no observed antecedent clinical signs.
AIM: The current study was performed to notice the tangible causes of sudden death among 51 out of 340 she-camels on a private farm in the eastern region of El Khafgi, Saudi Arabia.
METHODS: A retrospective cohort study design was conducted to investigate the sudden death of camels through microscopic examination of fecal matter to identify the gastrointestinal parasites, analysis of whole blood thin films to diagnose blood parasites, blood culturing to recognize bacterial infection as Pasteurella multicida, and macroscopic postmortem examination to identify the gastrointestinal adult worm. The quantity and composition of feed were also analyzed. Afterward, a commercial multiscreen Ag-ELISA kit technique determined the toxins of Clostridium perfringens (C. perfringens).
RESULTS: The results revealed that the incidence rate of sudden death was 15%. The sudden death occurred due to C. perfringens enterotoxins detected in the rumen, intestinal content, and intestinal wall. The enterotoxins and Alpha toxins were noticed, but the other toxin types, including Beta and Epsilon, could not be detected. All C. perfringens toxins were discovered to be negative in fecal matter. A significant association was reported between sudden death, she-camels age, and feeding habits as risk factors (p = 0.020 and 0.028, respectively). Risk factor assessment by relative risk (RR) revealed that the odds of RR of sudden death occurring among she-camels aged over two years were higher than those less than two years (2.24 CI 95%, 1.093-4.591). Furthermore, the odds RR of sudden death occurring due to exposure of she-camels to a concentrated ration of 18% were higher twice than those not exposed (2.346 CI 95%, 1.039-5.296).
CONCLUSION: Clostridium perfringens enterotoxaemia should be listed as a cause of sudden death in camels and the alteration in diet with 18% concentration feed changes the intestinal environment, which leads to C. perfringens proliferating and yielding potent toxins. More observations and interferences like regular immunization are recommended to reduce the disease and increase the awareness of the farmers of the importance of risk factors.
The present invention provides a formula of oolong wine (an oolong pellet, an oolong tablet, a tipsy oolong pill), and a preparation method of the oolong wine (an oolong pellet, an oolong tablet, a tipsy oolong pill), which belongs to a preparation method of medicated wine and serial products. The formula of the present invention is composed of 32 Chinese herbal medicines of element velour chicken, zokor, etc. In the method, herbs of the element velour chicken, lizard, etc. are steamed by wine until cooked, the medicines are washed by water, and the product can be drunk after being sealed and hoarded for 47 days with wine, mineral water, sodium benzoate, etc. The oolong wine, etc. of the present invention have the functions of dispersing thirst, clearing heat and resisting various kinds of cancerization, and can treat pathological symptoms of yin dampness, hectic fever, various kinds of carcinomatosis, leucocyte reduction caused by aplastic anemia, chemotherapy and radiotherapy, etc.
BACKGROUND: Gastric intramural hematoma is a rare disease. Here we report a case of spontaneous isolated gastric intramural hematoma combined with spontaneous superior mesenteric artery intermural hematoma.
CASE PRESENTATION: A 75-years-old man was admitted to our department with complaints of abdominal pain. He underwent a whole abdominal computed tomography (CT) scan in the emergency department, which showed extensive thickening of the gastric wall in the gastric body and sinus region with enlarged surrounding lymph nodes, localized thickening of the intestinal wall in the transverse colon, localized indistinct demarcation between the stomach and transverse colon, and a small amount of fluid accumulation in the abdominal cavity. Immediately afterwards, he was admitted to our department, and then we arranged a computed tomography with intravenously administered contrast agent showed a spontaneous isolated gastric intramural hematoma combined with spontaneous superior mesenteric artery intermural hematoma. Therefore, we treated him with anticoagulation and conservative observation. During his stay in the hospital, he was given low-molecular heparin by subcutaneous injection for anticoagulation therapy, and after discharge, he was given oral anticoagulation therapy with rivaroxaban. At the follow-up of more than 4 months, most of the intramural hematoma was absorbed and became significantly smaller, and the intermural hematoma of the superior mesenteric artery was basically absorbed, which also confirmed that the intramural mass was an intramural hematoma.
CONCLUSION: A gastric intramural hematoma should be considered, when an intra-abdominal mass was found to be attached to the gastric wall. Proper recognition of gastric intramural hematoma can reduce the misdiagnosis rate of confusion with gastric cancer.
Women who receive surgery for benign lesions including leiomyoma, adenomyosis, or ovarian cysts. We will obtain one 5\*5 cm omental fat and one 3\*3 cm subcutaneous adipose tissue during surgery.
An HPV immunization program is in place in Quebec since 2008. By 2020 18 birth cohorts of girls were eligible for vaccination. Vaccine uptake with at least one dose of vaccine was \>80%. With such a high vaccine uptake an important herd immunity might be expected. The main objective of this study is to measure the prevalence of different HPV types in unvaccinated sexually active boys aged 16 to 20 years. This is a cross sectional study which includes one visit for all participants. Self sampling technic is used. During this phase of the study a total of 681 boys will be recruited. An additional phase of the study will be conducted at the condition that the prevalence of HPV6/11/16/18/31/33/45/52 and 58 in unvaccinated boys will be at least 8.65%. The second phase of the study if conducted will measure the prevalence of the same HPV types in 681 vaccinated boys of the same age.
Immunization mobile stations (IMSs 80) collect patient information such as biographical data, previous vaccination data, medical history, medications in use, occupation, administration of recent vaccination, and disease symptoms.  IMSs 80 synchronize the patient information with information stored in a database 116 at a center 82 that is accessible to different groups of personnel based on different privileges and security measures. Patients can access electronic patient records created by the IMSs, and stored at the IMSs and/or a local server 140 and eventually at the data center, via telephone or computer (e.g., via web browser). IMSs can capture and store images of vaccination and disease symptom sites on patients. The database 116 allows for vaccination and disease tracking and disease control. IMSs 80 have vaccination recommendation engine, electronic patient consent forms, and are programmable to track adverse events and create follow-up reports after a vaccine is administered.
Objective: To explore the weight-loss, metabolism, and anti-reflux effect of laparoscopic sleeve gastrectomy combined with fundoplication (SGFD) as treatment of obesity complicated by gastroesophageal reflux disease (GERD) with the aim of identifying the best treatment for such patients. Methods: This was a retrospective cohort study. Relevant clinical data of 140 patients with obesity (body mass index≥30 kg/m2) complicated by GERD (confirmed by preoperative GerdQ score, gastroscope, upper gastrointestinal radiography, 24-hour pH monitoring of esophagus, and high-resolution esophageal manometry) who had undergone bariatric surgery in the Minimally Invasive Surgery, Hernia and Abdominal Surgery Department of the People's Hospital of Xinjiang Uygur Autonomous Region from January 2019 to February 2023 were collected. The participants were allocated to the following groups according to surgical procedure performed: sleeve gastrectomy group (SG group, 92 cases) versus SGFD (SGFD group, 48 cases). SGFD, a new type of anti-reflux weight loss surgery that achieves both anti-reflux and weight loss effects by a procedure involving "cutting first and then folding", was developed by our team. In this study, our main aim was to compare and analyze differences in outcomes between the SG and SGFD groups in terms of weight loss and improvements in metabolism and reflux 3 and 6 months postoperatively. Results: The 140 patients comprised 50 men and 90 women of average age 36.0±9.6 years and preoperative body mass index (BMI) (38.5±6.5) kg/m2. The average preoperative GERD score was 10.2±1.6. There were no significant differences in baseline characteristics between the SGFD and SG groups (all P>0.05). There were also no significant differences in postoperative hospital stay, intraoperative blood loss, or postoperative complications between the two groups (all P>0.05). However, the operation time was longer in the SGFD than SG group (137.5±10.5 minutes vs. 105.3±12.6 minutes, t=-15.131, P<0.001). Compared with preoperative values, fasting blood glucose, cholesterol, body mass, BMI, and GERD score were all lower 3 months postoperatively (all P<0.05). Six months postoperatively, triglyceride, uric acid, and DeMeester score were lower in the SGFD than SG group; however, the lower esophageal sphincter resting pressure was higher in the SGFD group (all P<0.05). There were no significant differences in weight loss indexes (body mass, BMI, percentage of excess body mass loss) or metabolic indexes (fasting blood glucose, triglyceride, cholesterol, and uric acid concentrations) between the SG and SGFD groups 3 and 6 months postoperatively (all P>0.05). However, anti-reflux indexes (GerdQ score, DeMeester score, and lower esophageal sphincter resting pressure) were all significantly better in the SGFD than SG group 6 months postoperatively (all P<0.05). Conclusion: Obese patients with GERD get good weight loss, metabolism improvement and anti-reflux effect after SGFD. SGFD is a safe and feasible surgical method, and its anti-reflux effect is better than SG at the 6th month after operation, so it is feasible.
OUTLINE:

Children attend the H-PACE program comprising educational lessons over 30 minutes, PA over 30 minutes, and healthy snacks twice a week (BIW) for 12 weeks. The educational component includes 30-minute lessons on PA, fruits and vegetables, and sleep, followed by fun and entertaining games and activities. The PA component (30-minutes) comprises a variety of enjoyable activities including warm-up, main activities (e.g., walk/run/jog and aerobic fun games), and cool-down. The snack component introduces children to tasty and healthy foods and teaches children the skills to enable them to select and prepare healthy snack foods at school and at home. Snack education lessons emphasize the benefits of fruit and vegetable intake, and include a discussion of food composition (e.g., fat content, sugar, sodium). Children prepare healthy snack foods at home with parents once a week (QW) by taking home fruit and vegetable boxes with recipes for family-based engaging activities. Children also wear an accelerometer to monitor activity for 7 days at baseline and during week 11-12. Parents may participate in an optional virtual peer support group on study.
PURPOSE: A vegetable extract mixture for preventing and treating atopic dermatitis and allergic dermatitis is provided to effectively reduce inflammation by reducing cytokines and to treat atopic dermatitis and allergic dermatitis. CONSTITUTION: A vegetable extract mixture for preventing and treating atopic dermatitis and allergic dermatitis contains 1-97 wt% of a Lophatherum gracile Brongn. extract, 1-97 wt% of an Eriobotryae folium extract, 1-97 wt% of an Orostachys fimbriatus extract, and 1-97 wt% of an Inula Britannica var. chinensis extract. The extracts are mixed in a weight ratio of 1-4:1-4:1-4:1-4. The concentration of the extracts with respect to a solvent is 2%(g/g) each. The extracts are a hot water extract or an alcohol extract. A pharmaceutical composition for treating atopic dermatitis and allergic dermatitis contains the vegetable extract mixture as an active ingredient. [Reference numerals] (AA) Positive control group; (BB) Negative control group; (CC) Example 5; (DD) Example 6; (EE) Example 7; (FF) Example 8; (GG) Example 9; (HH) Example 10
Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products, including AVONEX. In controlled clinical trials, injection site reactions (e.g., injection site pain, bruising or erythema) occurred in 18% of patients receiving AVONEX and 13% in the placebo group. These reactions included injection site inflammation (6%), injection site pain (8%), injection site mass (<1%), nonspecific reactions. 

Injection site abscesses and cellulitis and injection site necrosis have been reported in the postmarketing setting with interferon beta products, including AVONEX. Some cases required treatment with hospitalization for surgical drainage and intravenous antibiotics. 

Periodically evaluate patient understanding and use of aseptic self-injection techniques and procedures, particularly if injection site necrosis has occurred. Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis. For patients who continue therapy with AVONEX after injection site necrosis has occurred, avoid administration of AVONEX into the affected area until it is fully healed. If multiple lesions occur, change injection site or discontinue therapy until healing occurs.
The invention discloses a Chinese herb preparation for treating goat chronic lingering dysentery and a preparation method thereof. The Chinese herb preparation for treating the goat chronic lingering dysentery is prepared by, by weight, 8-12 parts of radix puerariae, 4-8 parts of radix scutellariae, 4-8 parts of coptis chinensis, 3-7 parts of large-headed atractylodes rhizomes, 4-8 parts of smoked plums, 3-7 parts of dried tangerine or orange peels, 3-7 parts of officinal magnolia bark, 6-10 parts of Chinese yams and 2-6 parts of liquorice roots. The radix puerariae serve as principal herbs, and therefore the functions of relieving the exterior syndrome and clearing away heat, lifting yang of the spleen and stomach to promote the secretion of saliva or body fluid and curing diarrhea are achieved. The coptis chinensis, the radix scutellariae and the large-headed atractylodes rhizomes have the functions of clearing away heat and drying dampness and invigorating the spleen and supplementing qi; the smoked plums astringe intestine to stop diarrhea and promote the secretion of saliva or body fluid; the dried tangerine or orange peels and the officinal magnolia bark have the function of regulating qi-flowing for strengthening the spleen; the Chinese yams have the functions of invigorating the spleen and benefiting the stomach and promoting digestion; the liquorice roots have the functions of clearing away heat and toxic materials and coordinating the other herbs. All the herbs are used in cooperation, and therefore the formula characteristics of treating both the liver and the spleen, giving consideration to qi and blood and eliminating pathogens to support healthy qi are embodied. The formula is reasonable, the treatment effect on the goat chronic lingering dysentery is remarkable, and no obvious toxic and side effects are generated.
The invention provides a system for modulating the expression of a target gene in a subject wherein a defined response element for a DNA binding domain modulates expression of said target gene. The invention system comprises two chimeric proteins, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, one of which is non-endogenous to the subject. In addition, the first chimeric protein contains a DNA binding domain to which the target gene is responsive and the second chimeric protein contains a transcription modulating domain, such as a transcription activator or a transcription repressor. In one embodiment of the invention, two invention systems form a dimer having the properties of a native heterodimer or homodimer. In another embodiment, only the first chimeric protein contains a DNA binding domain and only the second chimeric protein contains a transcription activating domain. The functional entity formed by association of the first and second chimeric proteins can be designed to transactivate transcription by complexing with a DNA binding recognition site that does not have the 2-half site format common to response elements for members of the steroid/thyroid hormone nuclear receptor superfamily. Thus, certain of the invention systems cannot functionally interact with endogenous proteins in the way that wild type receptors do. The invention further provides nucleic acid sequences encoding the invention chimeric proteins, cells containing such nucleic acid sequences, and methods for using the invention chimeric proteins to modulate expression of one or more non-endogenous genes in a subject organism.
Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic molecules encoding the peptides are also disclosed. Also disclosed is a method for making the compounds and use of such compounds, such as artificial organ, artificial implant or tubing, coated with a compound of the invention that inhibits complement activation. A method for making the compounds is disclosed which includes synthesizing the peptide by condensation of the amino acid residues or analogs thereof or comprising expressing a polynucleotide encoding the peptide or a concatemer of the peptide, which is post-translationally cleaved to form the peptdide. Also disclosed are compounds comprising a peptide having a sequence: Xaa1 - Xaa2 - Cys - Val - Xaa3 - Gln -Asp - Trp Gly - Xaa4 - His - Arg - Cys - Xaa5 - Xaa6 - Xaa7 (SEQ ID NO:15);  wherein:  Xaa1 is missing or is Gly; Xaa2 is Ile, Val, Leu, Ac-lle, Ac-Val, Ac-Leu or together with Xaa1 is dipeptide Gly-lle; Xaa3 is Trp or an analog of Trp that comprises a substituted or unsubstituted bicyclic aromatic ring component or two or more substituted or unsubstituted monocyclic aromatic ring components; Xaa4 is His, Ala, Phe or Trp; Xaa5 is L-Thr, D-Thr, Ile, Val, Gly, or together with Xaa6 and Xaa7 is tripeptide Thr-Ala-Asn; Xaa6 is missing or is Ala; and Xaa7 is missing or is Asn.
Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.
Bone cement implantation syndrome (BCIS) is a potentially serious complication after joint replacement surgery, resulting from bone marrow debris and cement embolisation, culminating in pulmonary and cardiovascular collapse. Echocardiography aids in diagnosis and management. We present a woman in her 80s with grade II BCIS. CT angiogram was inconclusive, but echocardiography revealed hyperechogenic material and right ventricular dysfunction, confirming the diagnosis. She received cardiovascular and respiratory support in a level II intensive care unit, showing full recovery of the right ventricle function when it was later reassessed. This potentially fatal condition is successfully managed if recognised early with adequate supportive care. Echocardiography might guide the diagnosis, consolidating supportive measures.
The desirable pharmacological properties and a broad number of therapeutic activities have made peptides promising drugs over small organic molecules and antibody drugs. Nevertheless, toxic effects, such as hemolysis, have hampered the development of such promising drugs. Hence, a reliable computational tool to predict peptide hemolytic toxicity is enormously useful before synthesis and experimental evaluation. Currently, four web servers that predict hemolytic activity using machine learning (ML) algorithms are available; however, they exhibit some limitations, such as the need for a reliable negative set and limited application domain. Hence, we developed a robust model based on a novel theoretical approach that combines network science and a multiquery similarity searching (MQSS) method. A total of 1152 initial models were constructed from 144 scaffolds generated in a previous report. These were evaluated on external data sets, and the best models were fused and improved. Our best MQSS model I1 outperformed all state-of-the-art ML-based models and was used to characterize the prevalence of hemolytic toxicity on therapeutic peptides. Based on our model's estimation, the number of hemolytic peptides might be 3.9-fold higher than the reported.